BioPharma Resources

Drug Trial Radar · NCT07221669

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

An Open-Label Study to Assess the Efficacy and Safety of Multiple Doses of Salanersen (BIIB115) Delivered Intrathecally to Treatment-Naïve, Presymptomatic Infants With Genetically Diagnosed Spinal Muscular Atrophy

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 28, 2026

Primary completion

Nov 28, 2028

Study completion May 29, 2032

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 42 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing signs or symptoms. Most people with SMA have changes in a gene called survival motor neuron 1, also known as SMN1. These changes lower the amount of SMN protein in their bodies. Without enough of this protein, motor neurons and muscles cannot work properly. A similar gene called SMN2 can help replace some of the lost SMN protein in the body. Salanersen works by helping the SMN2 gene to make more SMN protein. In this study, participants will have either 2 SMN2 copies or 3 SMN2 copies. The higher the copy number, the less severe the participant's SMA is. The main goal of this study is to see if starting salanersen before signs or symptoms appear can prevent signs or symptoms of SMA or make them less severe. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones. The main questions researchers want to answer in this study are: * How many participants with 2 copies of the SMN2 gene can sit without support at 12 months? * How many participants with 3 copies of the SMN2 gene can walk alone at 18 months? Researchers will also learn more about: * The effects on participants' motor symptoms and how many new movement milestones participants achieve. * How many participants stay free of SMA symptoms * How much salanersen gets into the fluid surrounding the brain and spinal cord. * How much salanersen gets into the blood. * How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug. This study will be done as follows: * First, participants will be screened to check if they can join the study. The screening period will be up to 28 days. * This is an "open label" study. This is a study in which the participants, study doctor, and site staff know which study drug participants are receiving. In this study, all participants will receive salanersen through an intrathecal injection, or one that is given into the fluid surrounding the brain and spinal cord. * There will be 2 parts in this study. During Part 1, participants will receive 2 doses of salanersen, about 12 months apart from each other. Part 1 will last up to 25 months. * During Part 2, participants will continue to receive salanersen. They will receive up to 3 doses, 12 months apart from each other. Part 2 will last up to 36 months. * During Part 1, participants will have up to 11 clinic visits and up to 3 phone calls. During Part 2, participants will have up to 7 clinic visits and up to 12 phone calls.

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • SalanersenDrug

    Administered intrathecally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Participants with 2 Survival Motor Neuron 2 (SMN2) Copies Sitting Without Support (for at Least 10 Seconds)Time frame: At Month 12
  2. Part 1: Percentage of Participants with 3 SMN2 Copies Walking Alone (for at Least 5 Steps)Time frame: At Month 18
  3. Part 2: Percentage of Participants Attaining and Maintaining World Health Organization (WHO) Motor MilestonesTime frame: Up to Day 1825

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Neurology Rare Disease Center

    Flower Mound, Texas · Recruiting

  • Childrens Hospital of the Kings Daughter Norfolk

    Norfolk, Virginia · Recruiting

  • Sydney Children's Hospital_Randwick

    Randwick, New South Wales, Australia · Recruiting

  • Hospital da Crianca de Brasilia

    Distrito Federal, Brazil · Recruiting

  • PSEG Centro de Pesquisa Clinica

    Sai Paula, Brazil · Recruiting

  • Instituto Da Criança HC FMUSP

    São Paulo, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Clinica MEDS La Dehesa_Lo Barnechea

    Lo Barnechea, Chile · Recruiting

  • Guangzhou Woman and Children's Medical Center_Guangzhou

    Guangzhou, China · Recruiting

  • Childrens Hospital of Fudan University_Shanghai

    Shanghai, China · Recruiting

  • The Third Affiliated Hospital of Zhengzhou University - North Campus

    Zhengzhou, Henan, China · Recruiting

  • Royal Institute of Child Neurosciences

    Ahmedabad, Gujarat, India · Recruiting

  • Japan Institute for Health Security National Center for Global Health and Medicine

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.